Literature DB >> 11494055

Cloning and expression of uridine/cytidine kinase cDNA from human fibrosarcoma cells.

K Koizumi1, Y Shimamoto, A Azuma, Y Wataya, A Matsuda, T Sasaki, M Fukushima.   

Abstract

Uridine/cytidine kinase which converts uridine and cytidine to their corresponding monophosphates is a rate-limiting enzyme involved in the salvage pathway of pyrimidine synthesis. We isolated cDNA encoding the enzyme from human fibrosarcoma cells, then determined its nucleotide sequence by the 5'-RACE method followed by confirmation employing the human genome DNA library. The isolated uridine/cytidine kinase cDNA (UCK cDNA) consisted of 786 nucleotides encoding 261 amino acids and was found to have approximately 70% homology with mouse UCK cDNA. Northern blot analysis of human leukemia RNAs with labeled UCK gene showed a single band at 1.6 kb to be UCK mRNA, and southern blot analysis of the UCK cDNA after digestion with BamHI, SacI and XbaI enzymes showed four band signals, suggesting the UCK gene to have at least 4 exons. A truncated form of UCK cDNA was expressed as the His-tag conjugated protein in Escherichia coli. The expressed and purified protein specifically converted uridine and cytidine to their corresponding monophosphates and also phosphorylated antitumor nucleosides such as 5-fluorouridine, cyclopentenyl-cytosine and 3'-C-ethynylcytidine. The present results suggest that our cloned human UCK cDNA encodes the correct amino acid sequence for UCK protein, showing high intracellular phosphorylation activity forward natural and synthetic pyrimidine nucleosides.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11494055

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  8 in total

Review 1.  Synapse formation is enhanced by oral administration of uridine and DHA, the circulating precursors of brain phosphatides.

Authors:  R J Wurtman; M Cansev; I H Ulus
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

2.  Quantum mechanics/molecular mechanics investigation of the mechanism of phosphate transfer in human uridine-cytidine kinase 2.

Authors:  Adam J T Smith; Ying Li; K N Houk
Journal:  Org Biomol Chem       Date:  2009-05-06       Impact factor: 3.876

Review 3.  Oral administration of circulating precursors for membrane phosphatides can promote the synthesis of new brain synapses.

Authors:  Mehmet Cansev; Richard J Wurtman; Toshimasa Sakamoto; Ismail H Ulus
Journal:  Alzheimers Dement       Date:  2007-12-21       Impact factor: 21.566

4.  A nucleoside anticancer drug, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression.

Authors:  Shunsuke Meike; Tohru Yamamori; Hironobu Yasui; Masato Eitaki; Akira Matsuda; Masami Morimatsu; Masakazu Fukushima; Yasundo Yamasaki; Osamu Inanami
Journal:  Mol Cancer       Date:  2011-07-28       Impact factor: 27.401

5.  Uridine-cytidine kinase 2 (UCK2): A potential diagnostic and prognostic biomarker for lung cancer.

Authors:  Yingjie Wu; Muhammad Jamal; Tian Xie; Jiaxing Sun; Tianbao Song; Qian Yin; Jingyuan Li; Shan Pan; Xingruo Zeng; Songping Xie; Qiuping Zhang
Journal:  Cancer Sci       Date:  2019-08-23       Impact factor: 6.716

6.  Inhibition of HIF-1alpha by the anticancer drug TAS106 enhances X-ray-induced apoptosis in vitro and in vivo.

Authors:  H Yasui; A Ogura; T Asanuma; A Matsuda; I Kashiwakura; M Kuwabara; O Inanami
Journal:  Br J Cancer       Date:  2008-10-14       Impact factor: 7.640

7.  Sensitivity of human cancer cells to the new anticancer ribo-nucleoside TAS-106 is correlated with expression of uridine-cytidine kinase 2.

Authors:  Yuji Shimamoto; Katsuhisa Koizumi; Hiroyuki Okabe; Hiromi Kazuno; Yuko Murakami; Fumio Nakagawa; Akira Matsuda; Takuma Sasaki; Masakazu Fukushima
Journal:  Jpn J Cancer Res       Date:  2002-07

Review 8.  Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases.

Authors:  An R Van Rompay; Magnus Johansson; Anna Karlsson
Journal:  Pharmacol Ther       Date:  2003-11       Impact factor: 12.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.